Add Yahoo as a preferred source to see more of our stories on Google. In the past month, I’ve talked to four different people who have either had a sinus surgery or an actual sinus fungal ball, so ...

accurate diagnosis depends on histologic examination and culturing [5]. Although special stains have been recommended, such as periodic acid-Schiff, Gridley versus fungus, and methenamine silver ...

New treatment option offers potential to reduce repeat surgeries ...

Allergic fungal rhinosinusitis (AFRS) is a long-term inflammatory sinus condition. It happens when fungus, such as mold, grows in your nasal passages and your immune system has a strong allergic ...

Allergic fungal rhinosinusitis (AFRS) is a fungal infection that affects your nasal passages and sinuses. Typical symptoms include nasal congestion and polyps. Medications and home treatments ...

Sinus aspergillosis is a fungal infection that affects the sinuses. People with weakened immune systems and respiratory conditions are more likely to develop this condition. Aspergillus is a mold that ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) and a ...

Priority Review approval extends dupilumab into AFRS with prior surgery, expanding sino-nasal indications beyond CRSwNP and representing the ninth FDA-approved indication across type 2 inflammatory ...

Approval covers adults and children ≥6 years with prior sinonasal surgery, representing the first FDA-cleared pharmacologic option specifically for AFRS and dupilumab’s ninth U.S. indication.

Please provide your email address to receive an email when new articles are posted on . Patients treated with isavuconazole as primary or salvage therapy for invasive fungal sinusitis experienced ...

What Is Dupixent, and Why Does It Matter? Dupixent (dupilumab) is a prescription medicine for treating various allergic conditions and is given as a shot under the skin. The FDA has now approved ...